Giaimo Benedetto Daniele, Robert-Finestra Teresa, Oswald Franz, Gribnau Joost, Borggrefe Tilman
Institute of Biochemistry, University of Giessen, Friedrichstrasse 24, 35392 Giessen, Germany.
Department of Developmental Biology, Erasmus MC, Oncode Institute, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
Cancers (Basel). 2021 Apr 1;13(7):1665. doi: 10.3390/cancers13071665.
Enzymes, such as histone methyltransferases and demethylases, histone acetyltransferases and deacetylases, and DNA methyltransferases are known as epigenetic modifiers that are often implicated in tumorigenesis and disease. One of the best-studied chromatin-based mechanism is X chromosome inactivation (XCI), a process that establishes facultative heterochromatin on only one X chromosome in females and establishes the right dosage of gene expression. The specificity factor for this process is the long non-coding RNA (), which is upregulated from one X chromosome in female cells. Subsequently, is bound by the corepressor SHARP/SPEN, recruiting and/or activating histone deacetylases (HDACs), leading to the loss of active chromatin marks such as H3K27ac. In addition, polycomb complexes PRC1 and PRC2 establish wide-spread accumulation of H3K27me3 and H2AK119ub1 chromatin marks. The lack of active marks and establishment of repressive marks set the stage for DNA methyltransferases (DNMTs) to stably silence the X chromosome. Here, we will review the recent advances in understanding the molecular mechanisms of how heterochromatin formation is established and put this into the context of carcinogenesis and disease.
诸如组蛋白甲基转移酶和去甲基酶、组蛋白乙酰转移酶和去乙酰酶以及DNA甲基转移酶等酶被称为表观遗传修饰因子,它们常常与肿瘤发生和疾病有关。研究最为深入的基于染色质的机制之一是X染色体失活(XCI),这一过程仅在雌性个体的一条X染色体上建立兼性异染色质,并确定基因表达的正确剂量。这一过程的特异性因子是长链非编码RNA(),它在雌性细胞的一条X染色体上上调。随后,被共抑制因子SHARP/SPEN结合,招募和/或激活组蛋白去乙酰酶(HDAC),导致活性染色质标记如H3K27ac的丢失。此外,多梳复合物PRC1和PRC2会导致H3K27me3和H2AK119ub1染色质标记广泛积累。活性标记的缺失和抑制性标记的建立为DNA甲基转移酶(DNMT)稳定沉默X染色体奠定了基础。在此,我们将综述在理解异染色质形成分子机制方面的最新进展,并将其置于癌症发生和疾病的背景下进行探讨。